Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

证券日报网讯 ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

在 HCC 中，多条信号通路失调，导致癌细胞不受控制地增殖、转移和复发。除了 HCC 中频繁改变且作为治疗靶点的受体酪氨酸激酶（RTK）通路外，参与细胞分化、端粒调节、表观遗传修饰和应激反应的通路也具有治疗潜力。研究关键信号通路及其抑制剂对于实现 HCC 治疗的进展至关重要。

Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a novel and highly selective FGFR2/3 dual inhibitor, which maintains efficacy ...

Compound 10 demonstrated broader potency against FGFR2/3 mutants acquired after the approved FGFR drug treatments. It also exhibited robust selectivity, sparing FGFR1/4, and showed minimal off ...

Experiments in model systems have shown that FGFR-specific inhibitors may be valuable in treating multiple myeloma, bladder and endometrial cancers. FGF1, FGF2 and FGF4 have been studied in ...